#truist-securities
Latest news and interesting information about truist-securities.
Truist cuts Lowe's price target to $255
Truist Securities cuts Lowe's price target to $255 from $280, maintaining Buy rating. Expense timing pressure expected to weigh on Q2 earnings.
Bill.com price target cut to $45 on take rate outlook
Truist Securities cuts Bill.com price target to $45 from $46, maintains Buy rating. Updated model reflects slower take rate expansion and cost-cutting measures.
Truist Starts Arcus Biosciences at Buy on RCC Potential
Truist Securities initiates Arcus Biosciences with Buy rating and $35 price target, citing casdatifan's potential in renal cell carcinoma and immunology pipeline.
Truist raises CG Oncology target to $82 on NMIBC data
Truist Securities raises CG Oncology price target to $82 from $77 on NMIBC data. Stock near 52-week high after 206% yearly gain.
...